Listed

Innate Pharma SA: Form 20-F for the period ended Dec 31, 2022

Filed with the SEC on Apr 6, 2023 and accepted by EDGAR at Apr 6, 2023, 06:41 ET.

Share

Share this page

Story card, 1080 × 1920

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.

Line itemPeriodValueXBRL concept
Revenue12 months2022-01-01 to 2022-12-31EUR 57.7mifrs-full:Revenue
Operating income12 months2022-01-01 to 2022-12-31−EUR 57.4mifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2022-01-01 to 2022-12-31EUR 0ifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2022-01-01 to 2022-12-31−EUR 58.1mifrs-full:ProfitLoss
Diluted EPS12 months2022-01-01 to 2022-12-31−EUR 0.73ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2022-01-01 to 2022-12-31−EUR 0.73ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2022-01-01 to 2022-12-31−EUR 19.2mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2022-01-01 to 2022-12-31EUR 535.0kifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2022-12-31EUR 84.2mifrs-full:CashAndCashEquivalents
Current assetsAt period end2022-12-31EUR 139.8mifrs-full:CurrentAssets
Total assetsAt period end2022-12-31EUR 207.9mifrs-full:Assets
Current liabilitiesAt period end2022-12-31EUR 41.3mifrs-full:CurrentLiabilities
Shareholders' equityAt period end2022-12-31EUR 54.2mifrs-full:Equity
Shares outstandingAt period end2022-12-3179,542,627 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001628280-23-010946. Last ingested by Listed: Oct 27, 2026, 07:14 ET. Listed shows no prices and gives no investment advice.